By FieldPulse Editorial · March 24, 2026
Tags: Policy, Pipeline
UCB will build its first major U.S. biologics manufacturing facility in Georgia, a $2 billion investment that positions the Belgian pharma company ahead of growing political pressure to onshore pharmaceutical production.
UCB announced Monday it will invest $2 billion to build a large-scale biologics manufacturing facility in Georgia, its first major domestic production site in the United States. The plant will be located near UCB's U.S. headquarters in the Atlanta area, deepening the company's footprint in a region that has become an increasingly significant hub for life sciences operations in the American Southeast. The announcement arrives at a moment when domestic pharmaceutical manufacturing has become a live political issue in Washington. Pressure from the current administration — and from both sides of t